Adiso Therapeutics
At Adiso, we create medicines to treat inflammatory diseases, to improve the lives of patients and their families. We believe that current therapeutic approaches are often inadequate to halt disease progression or run the risk of burdening the patient with significant safety concerns.
To tackle these challenges, we are advancing an innovative pipeline of multi-modal small molecules all with novel mechanisms of action and a precision therapeutic approach. Our approach to developing therapeutics delivered locally to the site of inflammation is clinically and scientifically differentiated.
ADS051 is a first-in-class, oral, gut-restricted modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis that has completed a Phase 1b MAD clinical trial and will be moving into Phase 2 development later this year. Adiso is also developing ADS032, a first-in-class small molecule that acts as a dual inflammasome inhibitor (NLRP3 & NLRP1) and is in advanced pre-clinical development for the treatment of respiratory and dermal inflammation.
ADISO Means
Movement Towards Balance
ADISO was named to reflect the movement toward a healthier more balanced immunological and inflammatory state. The word comes from two Greek derived phrases: AD (movement toward) and ISO (balance). We thought this best reflected our dedication to the patients seeking a balanced, healthier life; free from inflammatory conditions and the physical and mental burden they leave behind.
Our Mission
To rigorously follow innovative science blazing a trail to provide patients new therapies to treat their inflammatory diseases, developing novel medicines that are first in class and best in class.
Our Vision
Inspires us to create these medicines for the treatment of inflammatory diseases, improving the lives of patients and their families.
Our Values
Drive what we do every day and are the foundation of our achievements. They articulate what we stand for and are a reflection of the qualities that represent what it means to be an Adiso employee.
Our Development Pipeline
First-In-Class Small Molecule Modulator of Neutrophil Trafficking and Activation
Preclinical
IND Enabling
Phase 1
Phase 2
Phase 3
ADS051
Portfolio of First-In-Class Small Molecule Inhibitor of the NLRP3 and 1 Inflammasomes
Preclinical
IND Enabling
Phase 1
Phase 2
Phase 3
ADS032